Stifel analyst, Paul Matteis, reiterated his Hold rating on shares of Alexion Pharmaceuticals (NASDAQ: ALXN) after attending the American Society ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE